Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

To join this study, you must be at least 18 years old. You need to have been diagnosed with advanced (Stage IV) non-small cell lung cancer, and your cancer must have stopped responding to previous treatments. These past treatments should have included an immunotherapy drug and a type of chemotherapy that contains platinum.

If your cancer has specific genetic changes (like EGFR, ROS1, or others), you might also be eligible. If you have these changes, you must have already tried specific targeted treatments for them. For example, if you have EGFR mutations, you should have received a drug called osimertinib previously. The study team will check your medical history to make sure you meet all these requirements.

It's important that you are able to understand what taking part in a study means and are willing to sign a form agreeing to participate. This is called informed consent. People of all genders and ethnic backgrounds are welcome to apply.

The detailed plan for what taking part involves is not fully described in the brief summary. However, typically in clinical trials like this, you would have regular visits to the hospital or clinic. During these visits, doctors and nurses will monitor your health, perform physical exams, and likely take blood samples and scans (like X-rays or CT scans) to see how you're responding to the treatment. You would receive the study medication as prescribed by the research team. The study involves comparing different treatments, so you would be assigned to one of the treatment groups by chance. This study will be ongoing until the researchers have enough information to compare the treatments effectively. You will be monitored closely throughout the study and for a period afterwards.